Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Financing Clinical Trials

QUOTED. 18 June 2021. Harith Rajagopalan.

  • News

Executive Summary

Fractyl Health closed a $100m financing round to support ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses root causes of type 2 diabetes. CEO Harith Rajagopalan spoke of his hopes for the technology.

“We’ve seen from the clinical work that we’ve done that Revita has the potential to be a ‘backbone’ therapy in type 2 diabetes and other metabolic diseases.” – Harith Rajagopalan, CEO, Fractyl Health

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Financing Clinical Trials
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT144087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By